Veerhealth Care Ltd (NIYATILEAS) — shareholding pattern, promoter holding, financials and share price
About Veerhealth Care Ltd (NIYATILEAS)
Veerhealth Care Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as NIYATILEAS and on the BSE under scrip code 511523. Its ISIN is INE882C01035.
Incorporated in 1992, Veer Healthcare Ltd is in the business of trading, manufacturing and marketing research based ayurvedic medicines [1]
Veerhealth Care Limited is diversified in the pharmaceutical and personal care manufacturing sector, focusing on creating formulations of cosmetics and oral care products.
Since 2013, the company has expanded from infrastructure and finance into the pharma sector, clearly defining its scope towards cosmetics and personal care industries.
Listed peers in Pharmaceuticals: Curis Lifesciences Ltd, Samrat Pharmachem Ltd, Zenith Drugs Ltd, Bharat Immunological & Biological Corporation Ltd, Sunil Healthcare Ltd, Source Natural Foods & Herbal Supplements Ltd.
Valuation & Returns
10 Jul 2026At ₹38 a share on 10 Jul 2026, Veerhealth Care Ltd (NIYATILEAS) was valued at a price-to-earnings ratio of 140.73x against an industry P/E of 36.41x and a price-to-book of 3.42x on a book value of ₹11.11 per share as of Mar 2025. Solomo computes return on equity of 2.43% and return on capital employed of 6.12% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 140.73x
- Industry P/E
- 36.41x
- P/B
- 3.42x
- EPS (TTM)
- ₹0.27
- Book value / share
- ₹11.11
- ROE
- 2.43%
- ROCE
- 6.12%
- ROA
- 1.6%
- Debt / equity
- 0.22x
- Dividend yield
- 0%
- EBITDA margin
- 9.08%
- 52-week range
- ₹16.7 – ₹40.74
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Veerhealth Care Ltd (NIYATILEAS) reported revenue of ₹32.48 crore, net profit of ₹0.54 crore and earnings per share of ₹0.27. That compares with revenue of ₹16.67 crore and net profit of ₹0.39 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹16.76 crore and net profit ₹-0.35 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 9.64 | 13.28 | 13.22 | 16.67 | 32.48 |
| Net profit (₹ cr) | -0.07 | 1.58 | 0.41 | 0.39 | 0.54 |
| EPS (₹) | -0.05 | 0.79 | 0.21 | 0.2 | 0.27 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 25.41% | 7.29% | 20.09% | 26.10% |
| Profit growth | 52.45% | 4.22% | - | -4.88% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 31.91% of Veerhealth Care Ltd (NIYATILEAS) (up 0.41 pp QoQ). Market capitalisation was ₹76 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: HUF 6.74%, RISHABH FINTRADE 2.72%, SAMIR . MEHTA 1.99%, SHILPABEN ALPESHBHAI SHAH 1.54%, YASH ALPESHBHAI SHAH 1.5%, ALPA SUNIL CHHEDA 1.1%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 31.91% | - | - | - | 68.09% |
| Mar 2026 | 31.5% | - | - | - | 68.5% |
| Dec 2025 | 31.5% | - | - | - | 68.5% |
| Sep 2025 | 31.5% | - | - | - | 68.5% |
| Jun 2025 | 31.5% | - | - | - | 68.5% |
| Mar 2025 | 31.5% | - | - | - | 68.5% |
| Dec 2024 | 30.41% | - | - | - | 69.59% |
| Sep 2024 | 30.41% | - | - | - | 69.59% |